Kaissar Tabynov

Prof. Kaissar Tabynov


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2014 in Vaccine
Verified
Journal Article
Open access
KTKaissar Tabynov
Kaissar Tabynov
ZKZhailaubay Kydyrbayev
Zhailaubay Kydyrbayev
SRSholpan Ryskeldinova
Sholpan Ryskeldinova
BYBolat Yespembetov
Bolat Yespembetov
NZNadezhda Zinina
Nadezhda Zinina
ASAbylai Sansyzbay
Abylai Sansyzbay
This paper presents the results of a study of the immunogenicity and protectiveness of new candidate vector vaccine against Brucella abortus - a bivalent vaccine formulation consisting of a mixture of recombinant influenza A subtype H5N1 or H1N1 (viral constructs vaccine formulation) viruses expressing Brucella ribosomal protein L7/L12 and Omp16, in cattle. To increase the effectiveness of the candidate vaccine, adjuvants such as Montanide Gel01 or chitosan were included in its composition. Immunization of cattle (heifers aged 1-1.5 years, 5 animals per group) with the viral constructs vaccine formulation only, or its combination with adjuvants Montanide Gel01 or chitosan, was conducted via the conjunctival method using cross prime (influenza virus subtype H5N1) and booster (influenza virus subtype H1N1) vaccination schedules at an interval of 28 days. Vaccine candidates were evaluated in comparison with the positive (B. abortus S19) and negative (PBS) controls. The viral constructs vaccine formulations, particularly in combination with Montanide Gel01 adjuvant promoted formation of IgG antibodies (with a predominance of antibodies of isotype IgG2a) against Brucella L7/L12 and Omp16 proteins in ELISA. Moreover, these vaccines in cattle induced a strong antigen-specific T-cell immune response, as indicated by a high number of CD4(+) and CD8(+) cells, as well as the concentration of IFN-γ, and most importantly provided a high level of protectiveness comparable to the commercial B. abortus S19 vaccine and superior to the B. abortus S19 vaccine in combination with Montanide Gel01 adjuvant. Based on these findings, we recommended the bivalent vaccine formulation containing the adjuvant Montanide Gel01 for practical use in cattle.

10 April 2014 in Virology Journal
Verified
Journal Article
Open access
PDF file
KTKaissar Tabynov
Kaissar Tabynov
ASAbylai Sansyzbay
Abylai Sansyzbay
ZKZhailaubay Kydyrbayev
Zhailaubay Kydyrbayev
БYБолат Bolat Yespembetov
Болат Bolat Yespembetov
SRSholpan Ryskeldinova
Sholpan Ryskeldinova
AEAndrej Egorov
Andrej Egorov
We generated novel, effective candidate vaccine against Brucella abortus based on recombinant influenza viruses expressing the Brucella ribosomal protein L7/L12 or outer membrane protein (Omp)-16 from the NS1 open reading frame. The main purpose of this work was to evaluate the safety, immunogenicity and protectiveness of vaccine candidate in laboratory animals.

23 February 2022 in npj Vaccines
Verified
Journal Article
Open access
PDF file
KTKairat Tabynov
Kairat Tabynov
NTNurkeldi Turebekov
Nurkeldi Turebekov
MBMeruert Babayeva
Meruert Babayeva
GFGleb Fomin
Gleb Fomin
TYToktassyn Yerubayev
Toktassyn Yerubayev
KTKaissar Tabynov
Kaissar Tabynov
Recombinant protein approaches offer major promise for safe and effective vaccine prevention of SARS-CoV-2 infection. We developed a recombinant spike protein vaccine (called NARUVAX-C19) and characterized its ability when formulated with a nanoemulsion adjuvant to induce anti-spike antibody and T-cell responses and provide protection including against viral transmission in rodent. In mice, NARUVAX-C19 vaccine administered intramuscularly twice at 21-day interval elicited balanced Th1/Th2 humoral and T-cell responses with high titers of neutralizing antibodies against wild-type (D614G) and delta (B.1.617.2) variants. In Syrian hamsters, NARUVAX-C19 provided complete protection against wild-type (D614G) infection and prevented its transmission to naïve animals (n = 2/group) placed in the same cage as challenged animals (n = 6/group). The results contrasted with only weak protection seen with a monomeric spike receptor-binding domain (RBD) vaccine even when formulated with the same adjuvant. These encouraging results warrant the ongoing development of this COVID-19 vaccine candidate.

1 October 2014 in Vaccine
Verified
Journal Article
Closed access
KTKaissar Tabynov
Kaissar Tabynov
BYBolat Yespembetov
Bolat Yespembetov
ASAbylai Sansyzbay
Abylai Sansyzbay

1 August 2016 in Veterinary Microbiology
Verified
Journal Article
Closed access
KTKairat Tabynov
Kairat Tabynov
ASAbylay Sansyzbay
Abylay Sansyzbay
ZTZhanara Tulemissova
Zhanara Tulemissova
KTKaissar Tabynov
Kaissar Tabynov
SDSantosh Dhakal
Santosh Dhakal
MMMuratbay Mambetaliyev
Muratbay Mambetaliyev

26 July 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KTKaissar Tabynov
Kaissar Tabynov
MSMaxim Solomadin
Maxim Solomadin
NTNurkeldi Turebekov
Nurkeldi Turebekov
MBMeruert Babayeva
Meruert Babayeva
GFGleb Fomin
Gleb Fomin
KTKaissar Tabynov
Kaissar Tabynov
We developed a novel intranasal SARS-CoV-2 subunit vaccine called NARUVAX-C19/Nano based on the spike protein receptor-binding domain (RBD) entrapped in mannose-conjugated chitosan nanoparticles (NP). A toll-like receptor 9 agonist, CpG55.2, was also added as an adjuvant to see if this would potentiate the cellular immune response to the NP vaccine. The NP vaccine was assessed for immunogenicity, protective efficacy, and ability to prevent virus transmission from vaccinated animals to naive cage-mates. The results were compared with a RBD protein vaccine mixed with alum adjuvant and administered intramuscularly. BALB/c mice vaccinated twice intranasally with the NP vaccines exhibited secretory IgA and a pronounced Th1-cell response, not seen with the intramuscular alum-adjuvanted RBD vaccine. NP vaccines protected Syrian hamsters against a wild-type SARS-CoV-2 infection challenge as indicated by significant reductions in weight loss, lung viral load and lung pathology. However, despite significantly reduced viral load in the nasal turbinates and oropharyngeal swabs from NP-vaccinated hamsters, virus transmission was not prevented to naïve cage-mates. In conclusion, intranasal RBD-based NP formulations induced mucosal and Th1-cell mediated immune responses in mice and protected Syrian hamsters against SARS-CoV-2 infection but not against viral transmission.